Huadong Medicine Co., Ltd (SHE:000963)
China flag China · Delayed Price · Currency is CNY
26.62
+0.74 (2.86%)
Oct 30, 2026, 3:04 PM CST

Huadong Medicine Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
43,56343,20841,50840,26137,48934,418
Other Revenue
404.2404.2397.3362.43226145.56
43,96743,61241,90640,62437,71534,563
Revenue Growth
2.03%4.07%3.16%7.71%9.12%2.61%
Cost of Revenue
30,02029,50928,00627,46825,68623,969
Gross Profit
13,94714,10313,89913,15612,02810,595
Selling, General & Admin
8,0587,8717,8068,0667,5846,591
Research & Development
1,4191,7531,4261,2711,016979.64
Other Operating Expenses
401219.42214.72203.41205.31176.11
Operating Expenses
9,9599,9809,5589,5668,8737,788
Operating Income
3,9894,1224,3413,5903,1552,806
Interest Expense
-58.36-83.77-96.95-114.91-120.04-68.48
Interest & Investment Income
77.4782.5210494.05103.3580.4
Currency Exchange Gain (Loss)
13.9413.94-2.56-1.04-34.7-2.27
Other Non Operating Income (Expenses)
-62.27-31.46-130.59-29.65-27.16-31.93
EBT Excluding Unusual Items
3,9594,1044,2153,5383,0762,784
Impairment of Goodwill
-78.11-78.11----2.92
Gain (Loss) on Sale of Investments
-47.25-137.84-129.19-233.47-113.09-96.31
Gain (Loss) on Sale of Assets
1.32.26-5.464.328.26-0.03
Asset Writedown
-11.21-3.32-25.19-5.14-5.87-5.09
Other Unusual Items
191.24129.92246.61161.8765.6147.89
Pretax Income
4,0154,0164,3023,4663,0312,828
Income Tax Expense
597.78605.62807.33619.59498.5488.91
Earnings From Continuing Operations
3,4173,4113,4942,8462,5332,339
Minority Interest in Earnings
20.823.4917.92-7.54-33.41-37
Net Income
3,4383,4143,5122,8392,4992,302
Net Income to Common
3,4383,4143,5122,8392,4992,302
Net Income Growth
-7.02%-2.78%23.71%13.59%8.58%-18.38%
Shares Outstanding (Basic)
1,7531,7521,7521,7501,7501,750
Shares Outstanding (Diluted)
1,7541,7541,7531,7521,7501,750
Shares Change
-0.12%0.06%0.08%0.10%0.00%-0.00%
EPS (Basic)
1.961.952.001.621.431.32
EPS (Diluted)
1.961.952.001.621.431.32
EPS Growth
-6.91%-2.84%23.61%13.47%8.58%-18.37%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
2,2572,6712,0212,3231,1892,351
Free Cash Flow Per Share
1.291.521.151.330.681.34
Dividend Per Share
0.9300.9300.9300.5800.2900.290
Dividend Growth
0%0%60.35%100.00%0%26.09%
Gross Margin
31.72%32.34%33.17%32.38%31.89%30.65%
Operating Margin
9.07%9.45%10.36%8.84%8.37%8.12%
Profit Margin
7.82%7.83%8.38%6.99%6.63%6.66%
Free Cash Flow Margin
5.13%6.13%4.82%5.72%3.15%6.80%
EBITDA
5,0305,0455,1054,3183,7783,316
EBITDA Margin
11.44%11.57%12.18%10.63%10.02%9.59%
D&A For EBITDA
1,042922.92764.35727.64622.73509.65
EBIT
3,9894,1224,3413,5903,1552,806
EBIT Margin
9.07%9.45%10.36%8.84%8.37%8.12%
Effective Tax Rate
14.89%15.08%18.77%17.88%16.45%17.29%
Revenue as Reported
43,96743,61241,90640,62437,71534,563